To reach the 90-90-90 objectives, the amount of ARVs and diagnostics at treatment sites will need to at least double by 2025. To ensure their timely production and advocate for its scale up, WHO is working with UNAIDS, UNICEF, the Global Fund, PEPFAR, the Clinton Foundation Health Access Initiative, Avenir Health, USAID, and the CDC to forecast their global demand. They will present their assessment of the future demand for current and new ARVs for both adults and children, brief the audience about some of the procurement strategies that will contribute to their being affordable, and present on the future of HIV diagnostics, including point of care technology.

**PROGRAMME**

**Part I: Access to medicines**
Chair: Jos Perriens (WHO) & David Jamieson (PFSCM)

*Forecasted demand for current and new ARV medicines in LMIC, 2014-2024.*
Jos Perriëns, WHO, Sandeep Juneja, Medicines Patent Pool & Vineet Prabhu, Clinton Health Access Initiative

*Future uptake of Pediatric ARV formulations & pediatric ART growth.*
David Jamieson, Partnership for Supply Chain Management (of PEPFAR).

*Securing the future supply of ARVs treatment.*
Martin Auton (The Global Fund to Fight AIDS, TB and Malaria).

**Part II: Access to HIV diagnostics**
Chair: John Nkengasong (CDC): Global Vision of the future of HIV diagnostics in LMIC

*Projected significant growth of RDTs, CD4, viral load and Early Infant Diagnostic tests in LMIC.*
Jos Perriëns, WHO/HIV on behalf of the Technical Working group.

*Current and future uptake of new diagnostic technologies, in particular, POC testing in LMIC.*
Jason Williams (Partnership for Supply Chain Management (of PEPFAR)) and Zacharias Katz (Clinton Health Access Initiative).